Pay in 4 interest-free payments of $6.05 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
patients with these features should be strongly suspected of having MC4R -deficient obesity, and genetic evaluation should be considered
It is currently in Phase 3 clinical trials, and regulatory approval is expected to be sought once those trials concludepossibly by late 2025 or early 2026
[1] BPC 157 and the central nervous system Sikiric P, et al
.png)
NCT06588296 (TOGETHER-PsA) (80) is a Phase 3b, randomized, multicentre, open-label study examining the efficacy and safety of ixekizumab compared to ixekizumab concomitantly administered with tirzepatide in overweight or obese adult patients with active PsA and at least one weight-related comorbidity
US$ 24.08
US$ 22.33
US$ 29.47
US$ 22.57
US$ 24.55
:format(jpg)/f.elconfidencial.com%2Foriginal%2Ff27%2Fb3a%2F460%2Ff27b3a460e92bcdc8635b6aa1b0eff12.jpg)
US$ 27.84
US$ 22.08
US$ 20.72
US$ 24.07
